Charles River Laboratories International, Inc. $CRL Shares Sold by Amundi

Amundi lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 76.7% in the first quarter, Holdings Channel.com reports. The institutional investor owned 16,347 shares of the medical research company’s stock after selling 53,919 shares during the quarter. Amundi’s holdings in Charles River Laboratories International were worth $2,305,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Brooklyn Investment Group grew its stake in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after buying an additional 86 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its stake in shares of Charles River Laboratories International by 2.7% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company’s stock valued at $589,000 after buying an additional 102 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Charles River Laboratories International by 2.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company’s stock valued at $763,000 after buying an additional 105 shares in the last quarter. Veracity Capital LLC grew its stake in shares of Charles River Laboratories International by 3.4% in the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company’s stock valued at $496,000 after buying an additional 107 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its stake in shares of Charles River Laboratories International by 6.8% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,926 shares of the medical research company’s stock valued at $290,000 after buying an additional 123 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 4.2%

NYSE:CRL opened at $159.68 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $160.86 and its two-hundred day moving average is $148.94. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $230.02. The company has a market cap of $7.86 billion, a PE ratio of -120.06, a P/E/G ratio of 4.90 and a beta of 1.47.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. During the same quarter last year, the business posted $2.80 EPS. Charles River Laboratories International’s quarterly revenue was up .6% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of recent research reports. Evercore ISI increased their target price on Charles River Laboratories International from $180.00 to $190.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Wall Street Zen downgraded Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 17th. Barclays increased their price target on Charles River Laboratories International from $155.00 to $165.00 and gave the company an “equal weight” rating in a report on Thursday, August 7th. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $145.00 to $160.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Finally, Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and increased their price target for the company from $150.00 to $200.00 in a report on Wednesday, July 9th. Six investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $177.07.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. This represents a 3.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).